Updates on the Management of CINV From the 2014 June Congresses. Program Goals. Introduction. Introduction (cont). 3 Major Classes of Antiemetic Agents Used in CINV Prevention. Antiemetic Guidelines: Current Recommendations. NK-1 RAs: Aprepitant. Investigational NK-1 RAs. - PowerPoint PPT Presentation
TRANSCRIPT
Updates on the Management of CINV From the 2014 June
Congresses
Program Goals
Introduction
Introduction (cont)
3 Major Classes of Antiemetic Agents Used in CINV Prevention
Antiemetic Guidelines: Current Recommendations
NK-1 RAs: Aprepitant
Investigational NK-1 RAs
Investigational NK-1 RAs (cont)
Aprepitant vs Metoclopromide in Delayed CINV
Rolapitant in Patients Receiving MEC
Phase 3 Study Design
Rolapitant in Patients Receiving MEC
Efficacy Results
Rolapitant in Patients Receiving MECSafety
Rolapitant in Patients Receiving HEC
Study Design of 2 Phase 3 RCTs
Rolapitant in Patients Receiving HEC
Efficacy Results
NEPA: A Fixed Dose Oral Combination of Netupitant and
PalonosetronPrimary End Point Efficacy Results From 3 RCTs
NEPA + DEX vs Oral PALO + DEX in AC-based MEC
Multinational, Randomized, Double-blind Phase 3 Study
NEPA + DEX vs Oral PALO + DEX in AC-based MEC
Overall CR Rates Across Multiple Cycles
NEPA + DEX vs PALO + DEX in AC-Based MEC
Safety Across Multiple Cycles
NEPA + DEX vs PALO + DEX in AC-based MEC
Most Common TRAEs Across Multiple Cycles
Non-AC MEC
NEPA in Multicycle MEC and HECPhase 3 Study Design
NEPA in Multicycle MEC and HECPatient Baseline and Disease Characteristics
NEPA in Multicycle MEC and HEC Post-Hoc Analysis of No Emesis Rates (Cycle 1) in
Patients Receiving Carboplatin
Fosaprepitant in Non-AC MECPhase 3 Study Design
APF530 vs Palonosetron
Aprepitant in Pediatric PatientsPhase 3 Study Design